Related Experiment Video
Updated: Jul 17, 2026
Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
Published on: May 2, 2013
[Positive immunoregulation of thalidomide on human peripheral blood mononuclear cell cultures]
Yun Yang1, Wang-Gang Zhang, Yin-Xia Chen
1Department of Hematology, The Second Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an 710004, China.
Insights
Thalidomide enhances immune cell proliferation and cytotoxic activity in peripheral blood mononuclear cells (PBMNCs). This immunomodulatory effect, particularly increased IL-6 secretion, contributes to thalidomide's anti-myeloma action.
Area of Science:
- Immunology
- Pharmacology
- Oncology
Context:
- Multiple myeloma is a hematologic malignancy.
- Thalidomide is an established treatment for multiple myeloma.
- Understanding thalidomide's immunomodulatory mechanisms is crucial.
Purpose:
- Investigate thalidomide's effects on peripheral blood mononuclear cells (PBMNCs).
- Elucidate the immunoregulation mechanisms of thalidomide in multiple myeloma treatment.
- Assess impacts on cell proliferation, lymphocyte subsets, cytokine secretion, and cytotoxic activity.
Summary:
- Thalidomide enhanced proliferation of CD8+ T and NK cells in PHA-stimulated PBMNCs.
- Increased IL-6 secretion and enhanced PBMNC cytotoxic activity were observed.
- IFN-gamma secretion decreased, while IL-2 and IL-10 remained unaffected.
Impact:
- Thalidomide enhances cellular immune function, contributing to its anti-myeloma effects.
- Findings provide insights into thalidomide's immunomodulatory mechanisms.
- Supports the use of thalidomide in multiple myeloma therapy.
Abstract:
This study was purposed to investigate the effects of thalidomide on proliferation of peripheral blood mononuclear cells (PBMNCs), levels of lymphocyte subsets, secretion of cytokines and its killing activity, and to elucidate the immunoregulation mechanisms in treatment of multiple myeloma with thalidomide. The method of MTT was used to detect the effects of thalidomide on the proliferations and the cytotoxic activity of PBMNC; the flow cytometer was used to analyze the lymphocyte subsets; the ELISA was used to measure the concentrations of cytokines in culture supernatants. The results showed that thalidomide enhanced the proliferations of the CD8+ T, NK cells in PHA-stimulated PBMNC from healthy volunteers, increased the secretion of IL-6 significantly, and decreased the secretion of IFN-gamma, and the secretions of IL-2 and IL-10 were not affected. Compared with control group, at the same ratio of effectors to targets the thalidomide (5 microg/ml) could enhance the cytotoxic activity of PBMNC (P < 0.01), the cytotoxic activity was maximal when the ratio of effectors to targets was 40:1. It is concluded that thalidomide preferentially enhances the proliferations of CD8+ T, NK cells in PHA-stimulated PBMNC from healthy volunteers, and enhances the cytotoxic activity of PBMNC by increasing the secretion of IL-6 significantly, in short, thalidomide can exert anti-myeloma effects by increasing cellular immune function.
